Navigation Links
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
Date:5/15/2008

han 50 mL/min.

Avoid Pregnancy

REBETOL therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients during therapy and 6 months post- treatment. Patients should use at least two effective forms of contraception and have monthly pregnancy tests during therapy and for 6 months after completion of therapy. A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for 6 months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

Incidence of Adverse Events

There are no new adverse events specific to PEGINTRON as compared to INTRON A; however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEGINTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON.

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON but similar to INTRON A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically sign
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
2. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
3. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
4. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
7. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
8. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
9. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... 19, 2011 Southern Home Medical Equipment, Inc. ... healthcare professionals and equipment to medical institutions, announced ... for specialized solutions for respiratory therapy illnesses, Southern ...  The program provides specialized treatment for Sleep Apnea, ...
... Awarepoint Corporation , the leading provider of ... today announced it has acquired Patient Care ... unites Awarepoint,s unmatched ZigBee based technology platform with ... the industry,s leading all-inclusive enterprise-wide RTLS solution. PCTS ...
Cached Medicine Technology:Southern Home Medical Equipment Launches Respi-Care Respiratory Therapy Program 2Southern Home Medical Equipment Launches Respi-Care Respiratory Therapy Program 3Awarepoint Corporation Announces Acquisition of PCTS 2Awarepoint Corporation Announces Acquisition of PCTS 3Awarepoint Corporation Announces Acquisition of PCTS 4
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at ... how blocking a particular molecule in metastatic breast cancer ... number of lung metastases. BRI scientists have found in ... shrink tumors by 60 - 80 percent and can ... lung. The $1.8 million five-year grant comes from the ...
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2
... HLS ) announced today that its Board of Directors ... on its 6.5%,Series A Convertible Perpetual Preferred Stock, payable ... 2, 2008., About HealthSouth, HealthSouth is the ... states across the country and in,Puerto Rico, HealthSouth serves ...
... (Dec. 20, 2007) -- Using new approaches, an interdisciplinary ... in New York City has gained a view of ... difficulty in patients with borderline personality disorder -- shedding ... early days yet, but the work is pinpointing functional ...
... More Benefit Online Nurse Community, SAN DIEGO, ... professionals to connect with their peers are growing ... site rising to the top,designed exclusively for nursing ... with their peers. NurseConnect, (http://www.nurseconnect.com ) is a ...
... 21 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... application (sNDA) with the U.S. Food and Drug,Administration ... with,previously untreated multiple myeloma (MM). The filing is ... VISTA(1) trial, one of the largest,international, randomized clinical ...
... MURRYSVILLE, Pa., Dec. 21 RESPIRONICS, INC.,(Nasdaq: RESP ... merger,agreement pursuant to which Royal Philips Electronics (AEX: PHI, ... all of the outstanding,shares of Respironics for USD 66.00 ... approximately USD 5.1 billion. The offer price represents a,premium ...
... Upon an ex parte motion,by the Service Employees ... (TRO) was issued late on Thursday, December 20,by ... Michigan,enjoining the Michigan Department of Community Health, Manor ... Group from taking certain actions related to,completing the ...
Cached Medicine News:Health News:HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock 2Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 2Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 3Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 4Health News:Professional Networking Web Site, NurseConnect.com Launches Innovative Features 2Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 2Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 3Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 4Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 5Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 2Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 3Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 4Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 5Health News:Manor Care To Vigorously Contest TRO 2
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
... for low to medium throughput reading of entire ... one to three racks and reads in approximately ... exported via text files and a list of ... with other programs. System includes a USB HP ...
... Stainless steel workbench top ... is adjustable from 25"-34". Available ... configurations. Accessories include shelves, drawers, ... Terra is an expert in ...
... frames ensure cleanroom compatibility ... and chemical resistance. These ... user-friendly pnuematic controls for ... footring standard. Five leg ...
Medicine Products: